Terms: = Prostate cancer AND CACNA1D, CCHL1A2, Cav1_3, CACNL1A2, CACN4, CACH3, ENSG00000157388, 776
131 results:
1. Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical prostatectomy?
Flores JM; Vertosick E; Jenkins LC; Cooper J; Benfante N; Sjoberg D; Vickers AJ; Eastham JA; Laudone VP; Scardino PT; Nelson CJ; Mulhall JP
J Urol; 2024 Mar; 211(3):400-406. PubMed ID: 38194487
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic significance of surgery and radiotherapy in elderly patients with localized prostate cancer: establishing and time-based external validation a nomogram from SEER-based study.
Zhanghuang C; Zhu J; Li Y; Wang J; Ma J; Li L; Yao Z; Ji F; Wu C; Tang H; Xie Y; Yan B; Yang Z
BMC Urol; 2024 Jan; 24(1):12. PubMed ID: 38184526
[TBL] [Abstract] [Full Text] [Related]
3. Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: a population-based retrospective cohort study.
Kjaer TK; Andersen EAW; Ursin G; Larsen SB; Bidstrup PE; Winther JF; Borre M; Johansen C; Dalton SO
Lancet Oncol; 2024 Jan; 25(1):126-136. PubMed ID: 38048803
[TBL] [Abstract] [Full Text] [Related]
4. Development of machine learning prognostic models for overall survival of prostate cancer patients with lymph node-positive.
Peng ZH; Tian JH; Chen BH; Zhou HB; Bi H; He MX; Li MR; Zheng XY; Wang YW; Chong T; Li ZL
Sci Rep; 2023 Oct; 13(1):18424. PubMed ID: 37891423
[TBL] [Abstract] [Full Text] [Related]
5. Identification of risk factors and prediction models for secondary malignant neoplasms (SMNs)-free survival and SMNs-specific survival in testicular cancer survivors.
Fu H; Talluri S; Rai S; Liang L; Trivedi J; Ankem MK
World J Urol; 2023 Sep; 41(9):2413-2420. PubMed ID: 37530808
[TBL] [Abstract] [Full Text] [Related]
6. Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder cancer-How Long Is Cystoscopic Surveillance Necessary?
Ma J; Roumiguie M; Hayashi T; Kohada Y; Zlotta AR; Lévy S; Matsumoto T; Sano T; Black PC
Eur Urol Focus; 2024 Jan; 10(1):189-196. PubMed ID: 37442722
[TBL] [Abstract] [Full Text] [Related]
7. Different Types of Patient Health Information Associated With Physician Decision-making Regarding cancer Screening Cessation for Older Adults.
Schoenborn NL; Boyd CM; Pollack CE
JAMA Netw Open; 2023 May; 6(5):e2313367. PubMed ID: 37184836
[TBL] [Abstract] [Full Text] [Related]
8. cacna1d overexpression and voltage-gated calcium channels in prostate cancer during androgen deprivation.
McKerr N; Mohd-Sarip A; Dorrian H; Breen C; A James J; McQuaid S; Mills IG; McCloskey KD
Sci Rep; 2023 Mar; 13(1):4683. PubMed ID: 36949059
[TBL] [Abstract] [Full Text] [Related]
9. A model for predicting overall survival in bladder cancer patients with signet ring cell carcinoma: a population-based study.
Liu L; Li C; Wang Q; Yuan H; Wang Y
Eur J Med Res; 2023 Feb; 28(1):61. PubMed ID: 36732873
[TBL] [Abstract] [Full Text] [Related]
10. Modified the 8th AJCC staging system for patients with advanced prostate cancer: a study based on SEER database.
Sun C; Yang D; Zhu J; Zhou Y; Xiang C; Wu S
BMC Urol; 2022 Nov; 22(1):185. PubMed ID: 36384495
[TBL] [Abstract] [Full Text] [Related]
11. Nomograms and scoring system for forecasting overall and cancer-specific survival of patients with prostate cancer.
Zhou Y; Lin C; Zhu L; Zhang R; Cheng L; Chang Y
Cancer Med; 2023 Feb; 12(3):2600-2613. PubMed ID: 35993499
[TBL] [Abstract] [Full Text] [Related]
12. Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models.
Singh D; Gupta M; Sarwat M; Siddique HR
Crit Rev Oncol Hematol; 2022 Aug; 176():103751. PubMed ID: 35752426
[TBL] [Abstract] [Full Text] [Related]
13. [The value of relaxation time quantitative technique from synthetic magnetic resonance imaging in the diagnosis and invasion assessment of prostate cancer].
Song N; Wang T; Zhang D; Wang Z; Zhang SR; Yu J; Cai L; Ma AL; Zhang Q; Chen ZQ
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(15):1093-1099. PubMed ID: 35436808
[No Abstract] [Full Text] [Related]
14. PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial.
Ménard C; Young S; Zukotynski K; Hamilton RJ; Bénard F; Yip S; McCabe C; Saad F; Brundage M; Nitulescu R; Bauman G
BMC Cancer; 2022 Mar; 22(1):251. PubMed ID: 35260100
[TBL] [Abstract] [Full Text] [Related]
15. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract] [Full Text] [Related]
16. Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection.
Porcaro AB; Tafuri A; Panunzio A; Mazzucato G; Cerrato C; Gallina S; Bianchi A; Rizzetto R; Amigoni N; Serafin E; Cianflone F; Orlando R; Gentile I; Migliorini F; Zecchini Antoniolli S; Di Filippo G; Brunelli M; Pagliarulo V; Cerruto MA; Antonelli A
Int Urol Nephrol; 2022 Mar; 54(3):541-550. PubMed ID: 35044553
[TBL] [Abstract] [Full Text] [Related]
17. Variance of Tumor Grade at Radical prostatectomy With Assessment of Each Tumor Nodule Versus Global Grading.
Iakymenko OA; Briski LM; Punnen S; Nemov I; Lugo I; Jorda M; Parekh DJ; Gonzalgo ML; Kryvenko ON
Arch Pathol Lab Med; 2022 Aug; 146(8):1032-1036. PubMed ID: 34752602
[TBL] [Abstract] [Full Text] [Related]
18. Mapping the Patient-Oriented prostate Utility Scale From the Expanded prostate cancer Index Composite and the Short-Form Health Surveys.
Zamora V; Garin O; Pardo Y; Pont À; Gutiérrez C; Cabrera P; Gómez-Veiga F; Pijoan JI; Litwin MS; Ferrer M;
Value Health; 2021 Nov; 24(11):1676-1685. PubMed ID: 34711369
[TBL] [Abstract] [Full Text] [Related]
19. National cancer Information System Within the Framework of Health Insurance in Colombia: A Real-World Data Approach to Evaluate Access to cancer Care.
Hernández Vargas JA; Ramírez Barbosa PX; Valbuena-Garcia AM; Acuña-Merchán LA; González-Diaz JA; Lopes G
JCO Glob Oncol; 2021 Aug; 7():1329-1340. PubMed ID: 34473526
[TBL] [Abstract] [Full Text] [Related]
20. The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers.
Garrido MM; Ribeiro R; Pinheiro LC; Holdenrieder S; Guimarães JT
Clin Chem Lab Med; 2021 Oct; 59(11):1869-1877. PubMed ID: 34318651
[TBL] [Abstract] [Full Text] [Related]
[Next]
